Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selicrelumab + Vanucizumab/Bevacizumab in Advanced Solid Tumors
NCT02665416Phase 1Completed
- Sponsor
- Roche
- Start
- Jan 2016
- Primary completion
- Oct 2019
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 1, open-label trial of selicrelumab in solid tumor, ovarian carcinoma, head and neck squamous cell carcinoma (HNSCC) and 1 more (2 arms), sponsored by Roche. Primary endpoints: Percentage of Participants With Dose-Limiting Toxicities up to 42 months, Maximum Tolerated Dose of Selicrelumab in Combination With Vanucizumab up to 42 months and 6 more. Started Jan 2016; status: completed.
02
Drugs
selicrelumab
03
Conditions
solid tumorovarian carcinomahead and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02665416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02665416.